Xyzal shows significant improvements in quality of life for persistent allergic rhinitis sufferers

Paris, 9 June 2003 New data presented at the 22nd European Academy of Allergology and Clinical Immunology (EAACI), 7 - 11 June 2003, in Paris, France, today show that Xyzal® (levocetirizine) significantly improves patients' quality of life by 47.5% when compared to placebo, in patients with persistent allergic rhinitis (PER). Quality of life was assessed using a universally accepted, disease-specific method the Rhinitis Quality of Life Questionnaire (RQLQ). Significant improvements in quality of life were also seen with Xyzal® using a more generic scoring method, the SF-36 Physical Component Score (p<0.001).1

The XPERTTM study data also show that Xyzal® significantly improved symptoms of PER when compared to placebo over the first 4 weeks of the study (5.43 ± 0.15 vs. 6.56 ± 0.15). Symptom improvement which was seen on most individual symptoms as early as the first week was sustained over the 6 months of the study in patients treated with Xyzal® (p<0.001). Efficacy was assessed using Total Five Symptom Score (T5SS).1

These new Quality of Life and clinical data are from the XPERTTM (Xyzal in Persistent Rhinitis Trial) study, which looked at long-term treatment with Xyzal® of patients with PER. XPERTTM is the first large study investigating treatment of PER since it was newly-defined in the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines.

Allergic rhinitis was previously subdivided into seasonal, perennial and occupational, based on time of exposure to allergens. ARIA believed this subdivision to be less than satisfactory, and hence advocated a new classification of allergic rhinitis in new guidelines. The new classification is based on duration and severity, and is subdivided into "intermittent" or "persistent" and into "mild" or "moderate-severe". A diagnosis of PER is made when symptoms last for more than 4 days a week

Contact: Vicky Blonsky

Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:

(Date:10/30/2019)... ... 2019 , ... Amberdata Inc., the leading blockchain and cryptoasset ... DF Capital, Rising Tide Fund, and HWVP. The new investment will fuel ... position as the leading data provider of institutional-grade blockchain and cryptoasset data. ...
(Date:10/29/2019)... ... 2019 , ... Fujirebio Diagnostics, Inc., a consolidated subsidiary of ... the company’s Lumipulse® G whole PTH Assay for testing on its LUMIPULSE® G1200 ... glands; which are four small glands located behind the thyroid gland. The hormone ...
(Date:10/27/2019)... , ... October 26, 2019 , ... Since 2010, The ... reseller program. By prioritizing the success of their clients, they’ve earned a place on ... a row, and they’ve won many additional awards and accolades along the way. , ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... ... October 09, 2019 , ... As World Mental Health ... and high school students have improved neuro-cognitive executive skills to enhance learning and ... and apply lifelong social/interpersonal, leadership, problem-solving and coping skills, due to an innovative ...
(Date:10/10/2019)... SCOTTSDALE, Ariz. (PRWEB) , ... October 10, 2019 ... ... Pratia , the largest network of clinical research centers in Europe. All ... first site network in Europe to become trained and certified as Virtual Trial ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the global ... today announces that the U.S. Food and Drug Administration (FDA) has granted the ... temporary relief of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia ...
(Date:10/3/2019)... ... October 01, 2019 , ... ... and reset itself, announced the midway point of its randomized research trial for ... study is to measure the efficacy of a non-invasive technology which compares tones ...
Breaking Biology Technology:
Cached News: